Journal News

JLR: Using microRNAs to target cancer cells

Dawn Hayward
March 01, 2016

Lipids form the membranes of our cells and serve as rainy day fuel. However, cancer cells have a habit of dysregulating every possible pathway they can, including lipid metabolism, generating an overabundance of lipids. Fortunately, the body already produces molecules that have the potential to stop this dysregulation in its tracks: microRNAs.

Summary of the metabolic pathways altered in cancer that are described in this review

In a recent review in the Journal of Lipid Research, Marta Gómez de Cedrón and Ana Ramírez de Molina of the Madrid Institute of Advanced Studies delve into exactly which microRNAs can be used to target cancer cells.

Lipids, molecules known for their insolubility in water, are synthesized to provide membrane integrity and are signaling molecules used by downstream effectors in the cell. As an energy source, lipids are broken down via beta-oxidation, and the intermediates can be used in other metabolic pathways.

MicroRNAs, meanwhile, are small single-stranded RNA molecules that can stop the synthesis of proteins. They bind to mRNA transcripts in the cell and cause their degradation, preventing production of proteins that cancer cells so desperately need.

The authors of the JLR review discuss several lipid-metabolism enzymes that cancer cells rely on whose targeting could prevent the synthesis and dissemination of lipids altogether. For example, an enzyme called fatty acid synthase, which is involved in the making of lipids, is upregulated and overused in cancer cells. Activation of a microRNA targeting this gene may shut down production of this enzyme and turn off this essential pathway. Mono-acyl glycerol lipase, which is involved in storing these lipids, may also be targeted.

Why is all of this important? If researchers can use normal cells’ machinery to target cancer cells specifically, the cancer may be slowed or completely halted. In fact, scientists have used antisense oligonucleotides that bind to microRNAs and repress their action as well as primary microRNAs, which mimic RNA of choice and activate their function. These methods have been used as cancer therapy in clinical trials.

MicroRNAs stand out from conventional gene-therapy-based approaches and have a niche in lipid metabolism. They can be designed specifically to target a gene and serve as modulators rather than on/off switches. Increased lipid formation and breakdown in cancer cells creates vulnerability that might be taken advantage of by microRNAs. In addition, cancer as a whole involves a combination of many factors, and microRNAs could lead the attack as professional pathway regulators to reset the normal metabolic landscape.

Dawn Hayward

Dawn Hayward earned a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Sphingolipids show potential as biomarkers for multiple sclerosis
Journal News

Sphingolipids show potential as biomarkers for multiple sclerosis

December 01, 2020

Maria Podbielska and colleagues at the Hirszfeld Institute write in the Journal of Lipid Research about their finding that ceramide levels vary in active and inactive MS lesions in the nervous system.

World AIDS Day 2020
Health Observance

World AIDS Day 2020

December 01, 2020

Despite decades of research and amazing scientific advancements, HIV remains a global threat.

Will the coronavirus evolve to be less deadly?
News

Will the coronavirus evolve to be less deadly?

November 29, 2020

All pandemics eventually run their course. But history and science suggest many possible pathways. How might COVID-19 end?

Uncovering details of molecular Ferris wheels inside cell structures
News

Uncovering details of molecular Ferris wheels inside cell structures

November 28, 2020

Simulations on the nation’s fastest supercomputer confirm details of a molecular mechanism that cell organelles use to regulate the pH of their environment.

The NIH is turning the human reference genome into a pangenome
News

The NIH is turning the human reference genome into a pangenome

November 26, 2020

In 2000, the human genome was announced as completed. But it was filled with gaps, and did not represent humanity’s genetic diversity. Read and watch a short film about recent updates.

From the journals: MCP
Journal News

From the journals: MCP

November 25, 2020

A destructive disease can lurk in a citrus plant’s vascular system. Misfolded proteins offer a key to inflammation in liver disease. And proteomic studies provide clues about signaling linked to neurological disorders.